Analyst Reco. Biogen Inc.

Equities

BIIB

US09062X1037

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-06-05 pm EDT			5-day change	1st Jan Change
195.34 ^USD	-0.57%		-0.34%	+10.99%

Jun. 04	Biogen Receives FDA Breakthrough Therapy Designation for Salanersen for Spinal Muscular Atrophy	CI
Jun. 04	Biogen Gets FDA Breakthrough Designation for Spinraza Successor Salanersen	DJ

Analyst Reco.

May. 27	RBC Lifts Price Target on Biogen to $227 From $222, Keeps Outperform Rating	MT
May. 15	Piper Sandler Adjusts Price Target on Biogen to $225 From $214, Maintains Overweight Rating	MT
May. 14	Oppenheimer Raises Biogen Price Target to $300 From $275, Maintains Outperform Rating	MT
May. 01	Citigroup Adjusts Biogen Price Target to $200 From $190	MT
Apr. 30	Goldman Sachs Adjusts Biogen Price Target to $250 From $238	MT
Apr. 30	Guggenheim Adjusts Price Target on Biogen to $260 From $246	MT
Apr. 30	Goldman Sachs Adjusts Price Target on Biogen to $250 From $238	MT
Apr. 30	Bernstein Adjusts Price Target on Biogen to $200 From $201	MT
Apr. 30	Rothschild & Co Redburn Adjusts Price Target on Biogen to $190 From $180	MT
Apr. 30	Morgan Stanley Adjusts Price Target on Biogen to $206 From $200	MT
Apr. 29	Wedbush Raises Price Target on Biogen to $196 From $191 as 'Catalyst Engine Revving Up', Keeps Neutral Rating	MT
Apr. 29	RBC Capital Raises Biogen Price Target to $222 From $213	MT
Apr. 28	Morgan Stanley Adjusts Price Target on Biogen to $200 From $190, Maintains Equalweight Rating	MT
Apr. 24	Goldman Sachs Adjusts Price Target on Biogen to $238 From $231, Maintains Buy Rating	MT
Apr. 23	JPMorgan Adjusts Price Target on Biogen to $185 From $175, Maintains Neutral Rating	MT
Apr. 22	Biogen Shares Rise After UBS Upgrade	MT
Apr. 22	Biogen's Q1 Earnings Call to Focus on BIIB080 Data and Apellis Deal, Oppenheimer Says	MT
Apr. 22	Rothschild & Co Redburn Adjusts Biogen Price Target to $180 From $150, Maintains Neutral Rating	MT
Apr. 22	UBS Upgrades Biogen to Buy From Neutral, Adjusts Price Target to $225 From $185	MT
Apr. 20	Wells Fargo Upgrades Biogen to Overweight From Equalweight, Adjusts PT to $250 From $200	MT
Apr. 14	Biogen Shares Rise After Piper Sandler Upgrade	MT
Apr. 14	Piper Sandler Upgrades Biogen to Overweight From Neutral, Adjusts Price Target to $214 From $177	MT
Apr. 13	Citigroup Adjusts Price Target on Biogen to $190 From $215, Maintains Neutral Rating	MT
Apr. 07	RBC Capital Adjusts Biogen Price Target to $213 From $233, Maintains Outperform Rating	MT
Apr. 02	HC Wainwright Adjusts Price Target on Biogen to $237 From $228, Maintains Buy Rating	MT